Llwytho...
Glycoengineering of NK cells with glycan ligands of CD22 and selectins for B-cell lymphoma therapy
CD22, a member of Siglec family of sialic acid binding proteins, has restricted expression on B cells. Antibody-based agents targeting CD22 or CD20 on B lymphoma and leukemia cells exhibit clinical efficacy for treating these malignancies, but also attack normal B cells leading to immune deficiency....
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Angew Chem Int Ed Engl |
|---|---|
| Prif Awduron: | , , , , , , , , , , , , , , , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
2020
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7980786/ https://ncbi.nlm.nih.gov/pubmed/33314603 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/anie.202005934 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|